Short Sellers Become More Focused on Big Pharma

Photo of Chris Lange
By Chris Lange Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

The short interest data has been released for the June 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be big upside.

The June 15 short interest data have been compared with the previous figures, and for the selected stocks, short interest is mixed.

Pfizer Inc. (NYSE: PFE) saw its short interest increase to 73.77 million shares from the previous 62.91 million. In February, short interest spiked incredibly, and since that time it has slowly backed off. The highest short interest reading on the year was 207.4 million. Shares of Pfizer closed Wednesday at $34.23, within a 52-week trading range of $27.51 to $35.53.

Merck & Co. Inc. (NYSE: MRK) saw its short interest increase to 32.11 million shares from 31.49 million in the previous period. The current and previous readings are some of the highest in the past 52 weeks. Merck shares closed Wednesday at $58.24, in a 52-week trading range of $52.49 to $63.62.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) short interest fell to 5.87 million shares. The level for the previous settlement date was 6.47 million. Shares of Teva closed Wednesday at $59.37, in a 52-week range of $47.36 to $68.75.

ALSO READ: Short Sellers Get More Selective on Big Biotech

Bristol-Myers Squibb Co. (NYSE: BMY) saw its short interest rise to 23.38 million shares from the previous reading of 22.12 million. The past few readings, including the current one, are the lowest short interest of the year. Bristol-Myers shares closed Wednesday at $66.81, within a 52-week trading range of $47.34 to $69.86.

AbbVie Inc.‘s (NYSE: ABBV) short interest decreased to 86.38 million shares from the previous level of 92.46 million. Short interest has backed off its highest level year to date; the highest reading in the past 52-weeks was 111.88 million. Shares of AbbVie closed Wednesday at $69.22, in a 52-week trading range of $51.37 to $70.76.

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618